Results 11 to 20 of about 343,303 (317)

A real-world study of adverse drug reactions of two isocitrate dehydrogenase inhibitor based on the US FDA adverse event reporting system and VigiAccess databases [PDF]

Frontiers in Pharmacology
Background and objectivesIsocitrate dehydrogenase (IDH) inhibitor drugs (Enasidenib, Ivosidenib) restore normal metabolism and epigenetic regulation in cells, offering a precision-targeted therapeutic option for acute myeloid leukemia (AML) patients with
Mengmeng Peng, Mengmeng Peng, Qian Guo, Zihan Dang, Baiquan Zhang, Manjuan Li, Manjuan Li, Zixuan Wang, Zixuan Wang, Xuemian Lu, Xuemian Lu, Jie Lin   +11 more
doaj   +2 more sources

Differential isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 mutation-related landscape in intrahepatic cholangiocarcinoma. [PDF]

Oncologist
Abstract Background Patients with intrahepatic cholangiocarcinoma (ICC) are prone to recurrence and poor survival. Targeted therapy related to isocitrate dehydrogenase (IDH) is an extremely important treatment.
Xu S, Cao L, Chen R, Ye C, Li Q, Jiang Q, Yan F, Wan M, Zhang X, Ruan J.   +9 more
europepmc   +3 more sources

Isocitrate Dehydrogenase Inhibitors in Glioma: From Bench to Bedside [PDF]

Pharmaceuticals
Isocitrate dehydrogenase (IDH) mutant gliomas are a primary malignancy of the central nervous system (CNS) malignancies, most commonly affecting adults under the age of 55.
Merve Hazal Ser, Mason Webb, Anna Thomsen, Ugur Sener   +3 more
doaj   +2 more sources

Cerebrospinal fluid metabolomics identifies a key role of isocitrate dehydrogenase in bipolar disorder: evidence in support of mitochondrial dysfunction hypothesis

Molecular Psychiatry, 2016
Although evidence for mitochondrial dysfunction in the pathogenesis of bipolar disorder (BD) has been reported, the precise biological basis remains unknown, hampering the search for novel biomarkers.
N Yoshimi, C C Chau
exaly   +2 more sources

Expression of IDH1, ATRX, p53 in Diagnosis of Gliomas as Per 2016 WHO Classification [PDF]

Journal of Clinical and Diagnostic Research, 2023
Introduction: The 2016 World Health Organisation (WHO) classification of tumours of the Central Nervous System (WHO CNS 2016 classification) is used to classify diffuse gliomas as astrocytoma, Oligodendroglioma (ODG), glioblastoma which are three ...
Lokesh Kumar, Manjiri Karandikar, NS Mani, RC Nimbargi   +3 more
doaj   +1 more source

Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.

Neuro-Oncology, 2022
Isocitrate dehydrogenase (IDH) mutant gliomas are the most common adult, malignant primary brain tumors diagnosed in patients younger than 50, constituting an important cause of morbidity and mortality.
Julie J. Miller, L. G. Gonzalez Castro, S. McBrayer, M. Weller, T. Cloughesy, J. Portnow, O. Andronesi, J. Barnholtz-Sloan, B. Baumert, M. Berger, W. Bi, R. Bindra, D. Cahill, Susan M. Chang, J. Costello, C. Horbinski, Raymond Y Huang, R. Jenkins, K. Ligon, I. Mellinghoff, L. Nabors, M. Plattén, D. Reardon, D. Shi, D. Schiff, W. Wick, Hai Yan, A. von Deimling, M. J. van den Bent, W. Kaelin, P. Wen   +30 more
semanticscholar   +1 more source

Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas. [PDF]

PLoS ONE, 2015
Isocitrate dehydrogenase 1 gene mutations are found in most World Health Organization grade II and III gliomas and secondary glioblastomas. Isocitrate dehydrogenase 1 mutations are known to have prognostic value in high-grade gliomas.
Ming-Yang Li, Yin-Yan Wang, Jin-Quan Cai, Chuan-Bao Zhang, Kuan-Yu Wang, Wen Cheng, Yan-Wei Liu, Wei Zhang, Tao Jiang   +8 more
doaj   +1 more source

Pattern of Recurrence of Glioblastoma Versus Grade 4 IDH-Mutant Astrocytoma Following Chemoradiation: A Retrospective Matched-Cohort Analysis

Technology in Cancer Research & Treatment, 2022
Background and Purpose: To quantitatively compare the recurrence patterns of glioblastoma (isocitrate dehydrogenase-wild type) versus grade 4 isocitrate dehydrogenase-mutant astrocytoma (wild type isocitrate dehydrogenase and mutant isocitrate ...
James Stewart PhD, Arjun Sahgal MD, Aimee K M Chan MSc, Hany Soliman MD, Chia-Lin Tseng MD, Jay Detsky MD, PhD, Sten Myrehaug MD, Eshetu G Atenafu MSc, Ali Helmi MD, James Perry MD, Julia Keith MD, Mary Jane Lim-Fat MD, MSc, David G Munoz MD, MSc, Gelareh Zadeh MD, PhD, David B Shultz MD, PhD, Sunit Das MD, PhD, Catherine Coolens PhD, Paula Alcaide-Leon MD, Pejman Jabehdar Maralani MD   +18 more
doaj   +1 more source

Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma

Oncogene, 2021
Brain tumors actively reprogram their cellular metabolism to survive and proliferate, thus offering potential therapeutic opportunities. Over the past decade, extensive research has been done on mutant IDH enzymes as markers of good prognosis in ...
Gabriel Alzial, Ophélie Renoult, F. Paris, C. Gratas, A. Clavreul, C. Pecqueur   +5 more
semanticscholar   +1 more source

Stochastic Microsensors Based on Carbon Nanotubes for Molecular Recognition of the Isocitrate Dehydrogenases 1 and 2

Nanomaterials, 2022
Two three-dimensional (3D) stochastic microsensors based on immobilization of protoporphyrin IX (PIX) in single-walled carbon nanotubes (SWCNT) and multi-walled carbon nanotubes (MWCNT) decorated with copper (Cu) and gold (Au) nanoparticles were designed
Raluca-Ioana Stefan-van Staden, Catalina Cioates Negut, Sorin Sebastian Gheorghe, Paula Sfirloaga   +3 more
doaj   +1 more source